VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCC

Yasuhiro Funahashi, MD
Published: Thursday, May 26, 2016

Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Using human xenograft models, researchers found that the combination in this group of patients caused tumor regression and had no body weight loss. An immunohistochemistry analysis revealed a decrease of microvessel density in the lenvatinib and combination arms, as well as a decrease in the proportion of proliferative cells.

Results also showed that the treatment of lenvatinib in combination with everolimus caused significant antitumor effect in the xenograft models. These preclinical data provide a mechanism to support the significant clinical benefit observed in RCC with the combination of lenvatinib and everolimus.
Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Using human xenograft models, researchers found that the combination in this group of patients caused tumor regression and had no body weight loss. An immunohistochemistry analysis revealed a decrease of microvessel density in the lenvatinib and combination arms, as well as a decrease in the proportion of proliferative cells.

Results also showed that the treatment of lenvatinib in combination with everolimus caused significant antitumor effect in the xenograft models. These preclinical data provide a mechanism to support the significant clinical benefit observed in RCC with the combination of lenvatinib and everolimus.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x